Temozolomide (TMZ) is an alkylating agent currently used as first-line therapy for gliomas treatment due to its DNA-damaging effect. However, drug resistance occurs, preventing multi-cycle use of this chemotherapeutic agent. One of the major mechanisms of cancer drug resistance is enhanced activity of a DNA repair enzyme, O 6 -methylguanine-DNA-methyltransferase (MGMT), which counteracts chemotherapy-induced DNA alkylation and is a key component of chemoresistance. MGMT repairs TMZ-induced DNA lesions, O 6 -meG, by transferring the alkyl group from guanine to a cysteine residue. This review provides an overview of recent advances in the field, with particular emphasis on the inhibitors of MGMT and underlying mechanisms. Literature search was performed through PubMed and all relevant articles were reviewed, with particular attention to MGMT, its role in TMZ-resistant gliomas, effects of MGMT inhibitors and the underlying mechanisms. Several strategies are currently being pursued to improve the therapeutic efficacy of TMZ via inhibition of MGMT to reduce chemoresistance and improve overall survival. MGMT may be a promising target for the treatment of TMZ-resistant gliomas.
-methylguanine (O 6 -meG) lesion by transferring the alkyl group from guanine to a cysteine residue, which posts a major therapeutic challenge. Inhibition of MGMT with several O 6 -guanine derivatives and related compounds has been explored and shown to enhance TMZ-induced cytotoxicity in cancer cells. There is a challenge in overcoming dose-limiting myelosuppressive toxicity of TMZ while maintaining its efficacy. Well-designed clinical trials showing that inhibition of MGMT is clinically beneficial for patients with gliomas are lacking.
Open questions
Does MGMT as a target hold promise for the treatment of TMZ-resistant gliomas? Is increasing TMZ dose intensity by extended administration actually a beneficial strategy for inactivating MGMT? Is MGMT promoter methylation a favorable biomarker for glioblastoma? How to overcome dose-limiting myelosuppressive toxicity of TMZ while maintaining its efficacy? How to prevent chemoresistance to TMZ and reduce the doses of TMZ and thus its toxicities without compromise of its efficacy?
Alkylating agents such as TMZ are the principle first-line chemotherapeutic agents used for the treatment of recurrent high-grade glioma and have also been used to treat advanced malignant melanoma and other solid neoplasias.
1,2 Little progress has been made in the treatment of metastatic glioma and melanoma, mainly due to cancer cell resistance to chemotherapy. A variety of mechanisms account for cancer cell resistance to chemotherapy, which include decreased drug uptake into the cell, increased drug efflux, intracellular drug inactivation, repair of drug-induced damage, or resistance to drug-induced apoptosis. 3, 4 TMZ is a prodrug that undergoes spontaneous decomposition in solution at physiological pH to the reactive intermediate 5-(3-methyl-1-triazeno)imidazole-4-carboxamide, which methylates the N 7 and O 6 positions of guanine and the N 3 position of adenine. 5 The methyl adducts, O 6 -meG, N 7 -methylguanine (N 7 -meG), and N 3 -methyladenine (N 3 -meA) result in a continuous cycle of DNA base mismatch repair (MMR) with eventual strand breaks, ultimately leading to cellular apoptosis ( Figure 1 ). 6 Therefore, TMZ exerts its chemotherapeutic efficacy for cancer by inducing apoptosis of cancer cells. It has been demonstrated that TMZ-triggered apoptosis requires Fas/CD95/Apo-1 receptor activation in glioma cells with wild-type p53, whereas the same DNA lesion triggers the mitochondrial apoptotic pathway in p53-mutated glioma. 7 However, acquired chemoresistance to TMZ developed in cancer cells has been shown to be a major limitation to this therapy, as 490% of recurrent gliomas show no response to a second cycle of chemotherapy. 8 Several mechanisms are believed to have critical roles in the chemoresistance to TMZ. The primary mechanism involves MGMT, which is a small enzymatic protein acting to directly remove O 6 -meG from the O 6 -guanine position. 9 It has been demonstrated that MGMT repairs the principle O 6 -meG-alkylation site of TMZ, limiting its effects. High levels of MGMT are reported in the brain and other tumors and correlate with resistance to TMZ. 10 Interestingly, DNA MMR and poly(ADP-ribose) polymerase (PARP) may also contribute to chemoresistance. 11 The antitumor effect of TMZ is resulted from the induction of methyl adducts at several DNA bases: O6-guanine, N7-guanine, and N3-adenine. The base excision repair (BER) pathway is important in the repair of DNA damage at the N7-adenine and N3-guanine adducts, and high levels of BER activity can confer resistance to TMZ, similar to MGMT. The MMR system, which is critical for the removal of DNA replication errors leads to reiterative attempts to repair the damage, or a 'futile cycle' of DNA repair, ultimately leading to apoptosis. 12 Previous studies have shown that inhibition of MGMT increases TMZ sensitivity only in MMR-proficient cells but not in MMR-deficient cells. 13 Therefore, it is conceivable to consider MGMT as a potential therapeutic target for the treatment of cancers that are potentially resistant to TMZ.
In this review article, we will primarily present the rationale for combining inhibitors of MGMT with TMZ to improve the efficacy of treatment for neurological tumors, particularly gliomas. Moreover, the potential underlying mechanisms for resistance to TMZ chemotherapy will be discussed, with highlight of the important role of the DNA damage response pathways. -meG accounts for o8% of total alkylation, it exerts the greatest potential for apoptosis.
14 O 6 -meG is processed into DNA double-strand breaks (DSBs) in a DNA MMR-dependent manner, requiring two rounds of DNA replication (Figure 2) . 15, 16 These DSBs may then trigger apoptotic cell death in glioblastoma multiforme (GBM).
O
6 -meG is the best example of how a defined DNA lesion triggers the DNA damage response. Although this small DNA adduct does not block DNA replication, it occurs in MGMT lacking cancer cells and may be responsible for the majority of mutations, recombination, clastogenicity, and apoptotic effects of methylating agents that have the ability to methylate oxygen in DNA. 17 One of the key transducing kinases of the DNA replication checkpoint is the ataxia telangiectasia and Rad3-related kinase (ATR). ATR localizes to sites of stalled DNA replication forks, which is mediated by the ATRinteracting protein (ATRIP), a prerequisite for ATR. 18 Pairing (or mismatch) of O 6 -meG with thymine (i.e., O 6 -meG/T) is a substrate of MutSa/MutLa-dependent MMR. 19 It has been observed that MutSa bound to O 6 -meG/T stimulates phosphorylation of ATR/ATRIP and Chk1, and thus binding of MutSa to O 6 -meG/T lesions may be sufficient to activate the DNA damage response. 20 It is also conceivable that O 6 -meG/T mismatches directly lead to DSBs due to nuclease attack at single-stranded DNA (ssDNA) arising from the futile MMR process. Cells with O 6 -meG/T lesions have to pass through a second cell cycle where MMR processing the lesions leads to secondary DNA lesions, which interfere with DNA replication. Consequently, replication blockade and DSBs occur as a result of stalled replication forks and fork collapse. 16 Following alkylation stress, in the absence of MGMT, the repair proteins are required and are to be activated for recombination repair. Many other pathways are also involved in repairing DNA damage induced by alkylating agents, which include homologous recombination (HR), non-homologous end-joining (NHEJ), BER, polymerase bypass, and MMR. 21 Double-stranded DNA break (DSB) is a dangerous DNA lesion and if left unrepaired result in severe genomic instability. The two major pathways for repair of DSBs are HR and NHEJ. 21 HR leads to accurate repair, while NHEJ is intrinsically mutagenic. NHEJ modifies the broken DNA ends and ligates them together with no regard for homology, generating deletions or insertions. In contrast, HR uses an undamaged DNA template to repair the break, leading to the reconstitution of the original sequence. NHEJ is an errorprone process that relies on the coordinated actions of Ku70/ Ku80, DNA-PKcs, Artemis, XRCC4, and DNA ligase IV to rejoin the two ends of a broken DNA molecule. 22 HR uses meA DNA adducts are efficiently repaired by the BER pathway and normally contribute little to TMZ cytotoxicity in cancer cells. Methoxyamine binds to apurinic/apyrimidinic (AP) DNA damage sites produced by methylpurine glycosylase (MPG, blue circle), the first step in BER processing. Methoxyamine-bound AP sites are refractory to AP endonuclease cleavage, resulting in the blockage of the BER pathway, leading to strand breaks, disrupted replication, and increased cytotoxicity of TMZ. Chemistry of the lesion and the repair intermediates throughout the repair process are highlighted as the three major steps for BER: lesion recognition/strand scission, gap tailoring, and DNA synthesis/ligation sequence homology to perform an error-free break correction that preserves the original DNA sequence. The central reaction of the HR pathway, namely the homology search and strand invasion, is performed by Rad51-coated 39 ssDNA tails generated by DNA end resection of the break. 23, 24 The formation of this nucleoprotein filament at ssDNA is promoted and stabilized by BRCA2. 25, 26 Both Rad51 and BRCA2 are essential for HR in mammalian cells, although the functions of Rad51 and BRCA2 in other repair pathways have not been elucidated.
MGMT activity promotes resistance to TMZ
Overexpression of MGMT prevents cancer cells from death induced by alkylating agents with a correlation between MGMT activity and tumor drug resistance. 9 MGMT removes the O 6 -alkylguanine DNA adduct through covalent transfer of the alkyl group to the conserved active site, cysteine, and restores the guanine to normal. 27 After receiving a methyl-group from O 6 -meG, MGMT is inactivated and subjected to ubiquitinmediated degradation. A similar suicidal enzyme reaction occurs when MGMT transfers and accepts an alkyl group from -meG/T mismatches. 28 These mismatches are initially detected and processed by MutS and MutL homologs (MSH and MLH, respectively), which then signal to activate the ataxia telangiectasia-mutated kinase checkpoint kinase 2 (Chk2) and ATR-Chk1 pathways. This leads to the activation of a transient checkpoint in the second S phase and eventual cell cycle arrest at the G2 phase. 29 MGMT-mediated repair is unique among DNA repair pathways. First, it acts alone without relying on any other proteins or cofactors. It transfers the alkyl group to an internal cysteine residue in the protein, acting as both a transferase and an acceptor of the alkyl group. It inactivates itself after receiving the alkyl group from guanine, and thus is a suicidal protein. Finally, it repairs DNA lesions in a stoichiometric fashion. Thus, investigation of potential drug interactions that modulate MGMT could help improve the efficacy of chemotherapies utilizing alkylating agents. -BG, which is so far the most extensively studied direct MGMT inhibitor. 31 Another potent agent is PaTrin-2, a pseudosubstrate inactivator of MGMT, which was reported to be more potent than O 6 -BG in inactivating recombinant MGMT protein.
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-BG and PaTrin-2 have been shown to reverse the therapeutic resistance to TMZ by modulating MGMT expression in a variety of human tumor cell lines and xenograft models that include melanoma, brain, prostate, and colon cancers. 33, 34 However, many clinical trials with O 6 -BG or PaTrin-2 have observed an increase in toxicity or adverse events, resulting in a significant dose reduction of TMZ. This might explain why, in any of the reported clinical trials, the outcome has not been improved by the inclusion of O 6 -BG or PaTrin-2. In addition, in all the studies, myelosuppression manifested as neutropenia, leukopenia, and thrombocytopenia was mainly responsible for dose limitation. A recent study evaluated a combination of TMZ and O 6 -BG in patients with anaplastic glioma: only 3% of the former and 16% of the latter responded to therapy, and overall, grade 4 hematological events were observed in 48% of the patients. 35 In another phase II trial, 104 patients with metastatic melanoma were treated with TMZ alone or a combination of PaTrin-2 and TMZ on days 1-5 every 28 days for up to 6 cycles. 36 Combination with PaTrin-2 did not significantly influence the overall response rate (13.5 versus 17.3%) and the median time to disease progression (65.5 versus 68.0 days).
Resveratrol. Resveratrol is a naturally occurring compound that possesses anti-cancer effects. 37, 38 Resveratrol has been reported to reverse TMZ resistance by downregulation of MGMT in T98G glioblastoma cells through a NF-kBdependent pathway. 39 Combination with TMZ and Figure 3 Possible mechanisms of the anti-tumor effects of inhibitors of MGMT in sensitizing resistant cancer cells treated with the alkylating agent TMZ resveratrol decreases the 50% inhibiting concentration of TMZ and increases apoptosis in TMZ-resistant T98G cells. Lin et al. 40 indicated that TMZ-induced ROS/ERK-mediated autophagy protected glioma cells from apoptosis, and combined treatment with resveratrol and TMZ improved the efficacy of chemotherapy for brain tumors. Yuan et al. 41 demonstrated that resveratrol enhanced TMZ-mediated antitumor effects in GBM via a ROS-dependent AMPK-TSCmTOR signaling pathway. Therefore, resveratrol is a promising agent to overcome resistance to TMZ, and its effect on MGMT is one of the possible mechanisms.
Oncolytic viruses. Oncolytic viruses, such as adenoviruses and herpes simplex viruses (HSV), have been introduced into clinical trials as a new treatment for malignancies. 42 During viral infection, the extraordinary amount of exogenous viral DNA mimics the damaged DNA with DSBs that are processed by the cellular DNA-repair machinery. Unlike the DNA-damaging agents, viruses inactivate or manipulate the cellular DNA-repair system for the viruses' benefit. 43 Adenovirus E1A protein has been shown to efficiently inhibit the promoter of MGMT and thus may reduce the chemoresistance of cancer cells to TMZ. 44 A recent study revealed synergistic tumor cell killing by the combination of TMZ with oncolytic viruses, D-24-RGD. 44 The adenovirus E1A protein binds with p300 protein to inhibit the transcription of MGMT, leading to silencing of the MGMT promoter. It has been reported that combination of TMZ with a mutant HSV, G207, produced a synergistic effect on glioblastoma cell killing in vitro and in vivo, and the synergism depended on the activation of DNA repair pathways. 45 A recent study showed that the combination of G47-Delta and TMZ acted synergistically in killing glioblastoma stem cells through oncolytic HSVmediated manipulation of DNA damage responses, indicating that this strategy is highly efficacious in representative preclinical models and warrants clinical translation. 46 As combination of TMZ and an agent with a different mode of action makes the emergence of resistance to TMZ in cancer cells less likely, treatment with oncolytic viruses and DNAdamaging agents, such as TMZ, may result in a better therapeutic effect in gliomas.
Quinolone derivatives. Quinolone derivatives such as 2-phenyl-4-quinolones can induce cytotoxicity in many human cancer cell lines. 47, 48 It has been shown that a novel synthetic quinolone, 20-fluoro-6, 7-methylenedioxy-2-phenyl-4-quino-lone (CHM-1) inhibits the growth of hepatocellular carcinoma in vitro and in vivo.
48 CHM-1 also induces DNA damage in human osterogenic sarcoma cells and murine colorectal adenocarcinoma cells. 49, 50 Tipifarnib is synthesized by the condensation of the anion of 1-methylimidazole with a 6-(4-chlorobenzoyl) quinolone derivative. 51 In a phase I trial, tipifarnib was well tolerated at 300 mg bid given discontinuously (days 21/28) in 4-week cycles, concurrently with standard chemo/radiotherapy. 52 An ongoing phase II study should evaluate the efficacy of tipifarnib with TMZ in patients with newly diagnosed glioblastoma and not receiving enzyme-inducing antiepileptic drugs.
S-adenosylmethionine and S-adenosylhomocysteine.
Methylation of DNA and mRNA is controlled by levels and ratios of the intracellular S-adenosylmethionine (AdoMet) and S-adenosylhomocysteine (AdoHcy). A previous study showed that experimentally elevated AdoHcy levels significantly decreased MGMT mRNA levels by 450% in all MGMT-expressing cancer cell lines, which is most likely the result of impaired mRNA methylation. 53 Thus, inhibition of MGMT expression by alterations in AdoMet/AdoHcy ratio could be used as a novel pharmacological strategy to improve the responsiveness to TMZ and other alkylating agents.
Inhibition of PARP and BER pathway may be alternative strategies to enhance TMZ activity Poly(ADP-ribosyl)ation is a ubiquitous protein modification found in mammalian cells that modulates many cellular responses, including DNA repair. 54 An alternative strategy to enhance TMZ activity is to inhibit PARP, mainly PARP-1 and PARP-2 ( Figure 4) . 55 It is hypothesized that PARP inhibition is able to restore TMZ activity due to a change in the cytotoxicity locus of TMZ from O 6 -meG to N 7 -meG and N 3 -meA. 55 Majority of TMZ-induced lesions (N 7 -meG and N 3 -meA) are substrates of the BER pathway, and thus the BER pathway has emerged as an attractive target for reversing TMZ resistance (Figure 4) . 56 Inhibition of BER pathway leads to the accumulation of repair intermediates that induce energy depletion-mediated cell death, and TMZ-induced cell death via BER inhibition is dependent on the availability of nicotinamide adenine dinucleotide (NAD þ ). It has been shown that inhibition of both BER and NAD þ biosynthesis significantly sensitizes glioma cells with elevated expression of MGMT. 56 Therefore, dual targeting these two interacting pathways (BER and NAD þ biosynthesis) may be an effective treatment for recurrent and resistant GBM.
Increasing TMZ dose intensity by extended administration: a beneficial strategy for inactivating MGMT?
As a suicide enzyme, MGMT is inactivated following each reaction. Therefore, theoretically, if the rate of DNA alkylation outpaces the rate of MGMT synthesis, the enzyme would be depleted. This property leads to the exploration of extended dose-dense TMZ regimens, with the idea that they could potentially deplete MGMT in tumor cells by overwhelming the cells' ability to synthesize MGMT, which might enhance therapeutic activity. 57 The concept of MGMT depletion was validated by Tolcher et al., 58 who showed that MGMT enzyme activity was depleted in peripheral blood mononuclear cells during treatment with TMZ for either 7 consecutive days every 14 days (7 of 14-day regimen) or 21 consecutive days every 28 days (21 of 28-day regimen).
The originally approved TMZ dosing regimen is 150-200 mg/m 2 per day (days 1-5 every 28-day cycle (5 of 28 days)). However, extended dosing regimens (i.e., 7 of 14 days, 21 of 28 days, 6 of 8 weeks, or continuously daily) allow for administration of a higher cumulative dose per cycle and have been shown to achieve a prolonged MGMT depletion and higher levels of TMZ at the site of the central nervous system, which may enhance cytotoxic activity. 59 Phase I trials have shown that such a strategy effectively depletes MGMT levels while permitting an almost two-fold greater level of exposure to the drug with minimal additional toxicity. 60 It has been reported that extended administration of low-dose TMZ sensitizes leukemic blasts to conventional doses of TMZ in TMZ-refractory patients, and MGMT activity can be reduced by approximately 80% in patients treated with this dosing schedule. 58, 61 These could be due to the fact that extended administration of TMZ, even at relatively low daily doses, leads to significant and prolonged depletion of MGMT activity, which may allow the patients to tolerate the increased systemic adverse events and enhance the anti-tumor activity of the agent. Despite these encouraging findings, two recent randomized controlled trials failed to produce overall survival benefit of increasing TMZ dose intensity by extended administration in recurrent and newly diagnosed gliomas, which casts concerns on the usefulness of this strategy. 62, 63 MGMT promoter methylation is a favorable biomarker for glioblastoma MGMT methylation status, an indicator of gene silencing, emerges as a potentially important molecular test to determine which patients with glioblastoma will benefit and should receive TMZ. 64 The MGMT promoter is typically reported methylated in 30-60% of glioblastomas and in 30-90% of lowgrade gliomas. [65] [66] Several trials have shown that MGMT promoter methylation correlates with better outcome of therapy. 67 Wick et al.
68
reported that TMZ chemotherapy produced no benefit in patients without MGMT promoter methylation in elderly patients with anaplastic astrocytoma or glioblastoma. Malmströ m et al. 69 showed that patients treated with TMZ who had MGMT promoter methylation had significantly longer OS than those without (9.7 versus 6.8 months). Similarly, Lechapt-Zalcman et al. 70 also showed that patients with glioblastomas who harbored MGMT methylation had a significantly longer OS compared with patients who had wild-type MGMT (21.7 versus 15.1 months; P ¼ 0.025). In addition, it has been shown that treatment with radiotherapy plus chemotherapy or chemotherapy alone, compared with radiotherapy alone, achieves longer PFS for patients with MGMT methylation but not in those without. 71 Low MGMT expression and MGMT promoter methylation are both predictive markers for slower tumor progression in patients with glioblastoma. 72 Thus, MGMT promoter methylation may be a useful biomarker to stratify glioblastoma patients whether or not to receive treatment with alkylating agents. However, not all clinical trials have demonstrated the association of MGMT methylation and better responses. [73] [74] [75] Therefore, well-designed clinical trials are required to provide convincing evidence showing that inactivation of MGMT is clinically beneficial.
Conclusions
TMZ, an alkylating agent, has a prominent role in gliomas by inducing DNA damage and cell apoptosis. However, resistance to TMZ emerges with prolonged treatment, mainly due to MGMT, which repairs O 6 -meG lesion, which posts a major therapeutic challenge. Thus, inhibition of MGMT with several O 6 -guanine derivatives and related compounds have been explored and shown to enhance TMZ-induced cytotoxicity in cancer cells. In addition, MGMT promoter methylation is a favorable biomarker for glioblastoma. Currently, there is a challenge in overcoming dose-limiting myelosuppressive toxicity of TMZ while maintaining its efficacy. Well-designed clinical trials are required to provide convincing evidence showing that inhibition of MGMT is clinically beneficial for patients with gliomas by preventing chemoresistance to TMZ and reducing the doses of TMZ and thus its toxicities without compromise of its efficacy. It is, however, anticipated that, with the availability of tumor-targeting strategies, MGMT as a target holds promise for the treatment of TMZ-resistant gliomas. 
